Evotec SE ADR (EVO): Next-Year EPS Estimate 82.81%
As of 2026-06-04, Evotec SE ADR (EVO) has a next-year EPS growth estimate of 82.81%.
On 2026-05-21, analyst consensus for EVO's next-year EPS growth shifted from 82.87% to 82.81% — a negative change of 0.06 percentage points. The revised estimate has been sustained across 11 subsequent trading sessions. Current-year growth is projected at -16.16%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 82.81%
- EPS growth this year
- -16.16%
- EPS next quarter (est)
- $0.01
- Last price
- $2.97
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 82.81% | -16.16% | $0.01 | $2.97 |
| 2026-06-03 | 82.81% | -16.16% | $0.01 | $2.89 |
| 2026-06-02 | 82.81% | -16.16% | $0.01 | $2.95 |
| 2026-06-01 | 82.81% | -16.16% | $0.01 | $3.07 |
| 2026-05-31 | 82.81% | -16.16% | $0.01 | $3.07 |
| 2026-05-28 | 82.81% | -15.46% | $0.01 | $2.96 |
| 2026-05-27 | 82.81% | -15.46% | $0.01 | $2.87 |
| 2026-05-26 | 82.81% | -15.46% | $0.01 | $2.91 |
| 2026-05-25 | 82.81% | -15.46% | $0.01 | $3.03 |
| 2026-05-24 | 82.81% | -15.46% | $0.01 | $3.03 |
| 2026-05-21 | 82.81% | -15.46% | $0.01 | $2.99 |
| 2026-05-20 | 82.87% | -15.70% | $0.01 | $2.84 |
| 2026-05-19 | 82.87% | -15.70% | $0.01 | $2.78 |
| 2026-05-18 | 82.87% | -15.70% | $0.01 | $2.74 |
| 2026-05-17 | 82.87% | -15.70% | $0.01 | $2.70 |
| 2026-05-14 | 82.87% | -15.70% | $0.01 | $2.72 |
| 2026-05-13 | 82.87% | -15.70% | $0.01 | $2.71 |
| 2026-05-12 | 82.87% | -15.70% | $0.01 | $3.00 |
| 2026-05-11 | 82.87% | -15.70% | $0.01 | $3.06 |
| 2026-05-10 | 79.05% | -11.87% | $0.01 | $3.07 |
| 2026-05-07 | 75.21% | -7.91% | $0.19 | $3.05 |
| 2026-05-06 | 65.56% | 19.17% | -$0.11 | $3.24 |
| 2026-05-05 | 65.56% | 19.11% | -$0.14 | $3.20 |
| 2026-05-04 | 65.56% | 19.11% | -$0.14 | $3.12 |
| 2026-05-03 | 65.56% | 19.11% | -$0.14 | $3.09 |
| 2026-04-30 | 65.94% | 20.16% | -$0.14 | $3.11 |
| 2026-04-29 | 65.94% | 20.16% | -$0.14 | $2.94 |
| 2026-04-28 | 65.94% | 20.16% | -$0.14 | $2.98 |
| 2026-04-27 | 65.94% | 20.16% | -$0.14 | $3.14 |
| 2026-04-26 | 65.94% | 20.16% | -$0.14 | $3.15 |
Recent News
- Evotec Appoints Dr. Ingrid Muller as Chief Operating OfficerACCESSWIRE
- Evotec SE (EVOTF) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue ChallengesGuruFocus.com
- Delta Air Lines heads earnings slateMarketWatch
- What To Expect From Evotec SE (XTER:EVT) Q4 2025 EarningsGuruFocus.com
- Evotec Nominates Dieter Weinand as Supervisory Board ChairmanACCESSWIRE
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Evotec SE ADR's next-year EPS growth estimate?▾
As of 2026-06-04, Evotec SE ADR (EVO) has a next-year EPS growth estimate of 82.81%, based on analyst consensus.
When was the latest EPS estimate revision for EVO?▾
The most recent revision occurred on 2026-05-21, when analysts adjusted the next-year EPS growth estimate from 82.87% to 82.81%.
What sector and industry does Evotec SE ADR belong to?▾
Evotec SE ADR operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. EVO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Evotec SE ADR (EVO) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports